Proteinuria Therapeutics Market
- 2026 年市場規模
- USD 24.50 Bn
- 2033 年預估規模
- USD 73.40 Bn
- 年複合成長率 CAGR
- 17.2%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Proteinuria Therapeutics Market, By Drug Class (Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Antagonists (ARBs), Diuretics, and Others), By Route of Administration (Oral and Intravenous), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
The Proteinuria Therapeutics Market is estimated to be valued at USD 24.50 Bn in 2026 and is expected to reach USD 73.40 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 17.2% from 2026 to 2033. The Proteinuria Therapeutics Market develops and provides treatments for proteinuria, a condition marked by excess protein in the urine that often signals kidney damage or disease. These therapeutics work to reduce protein excretion, slow the progression of kidney disorders, and manage complications such as hypertension and cardiovascular issues. By addressing the root causes and symptoms of proteinuria, these treatments help patients achieve better outcomes, improve quality of life, and maintain long-term kidney health.
Pharmaceutical research advancements and a deeper understanding of renal pathophysiology are driving the creation of novel proteinuria therapeutics, including targeted therapies and combination treatments. The market also benefits from rising awareness of kidney disorders, enhanced diagnostic tools, and increasing use of personalized treatment approaches. As healthcare providers prioritize early detection and effective management of chronic kidney conditions, the demand for proteinuria therapeutics grows, encouraging innovation, improving patient care, and enabling the introduction of more effective treatment options worldwide.
Market Dynamics
The Proteinuria Therapeutics Market grows mainly due to the rising prevalence of kidney-related disorders and increasing awareness of early diagnosis and treatment. Because proteinuria often indicates chronic kidney disease (CKD) or other renal complications, healthcare providers prioritize timely intervention. They actively manage proteinuria to prevent kidney damage and reduce associated cardiovascular risks. This focus on early detection and comprehensive care drives the demand for effective proteinuria therapeutics in hospitals, clinics, and specialized treatment centers.
Technological advancements and ongoing research significantly influence market dynamics. Pharmaceutical companies are developing innovative therapies, including targeted treatments, combination drugs, and biologics, to address the underlying causes of proteinuria more effectively. A deeper understanding of renal pathophysiology and the mechanisms behind proteinuria allows these companies to design safer and more efficient treatment options. Moreover, improvements in diagnostic tools and monitoring techniques help healthcare providers track disease progression and treatment response, supporting wider adoption of these therapeutics.
Regulatory support, expanding healthcare infrastructure, and personalized medicine approaches also shape market growth. Governments and healthcare organizations promote early intervention and preventive care for chronic kidney conditions. Pharmaceutical companies raise awareness among patients and providers through educational campaigns, encouraging broader acceptance of proteinuria treatments. As stakeholders continue to emphasize kidney health and improved patient outcomes, these factors collectively drive innovation, accessibility, and global expansion in the proteinuria therapeutics market.
Key Features of the Study
• This report provides in-depth analysis of the Proteinuria Therapeutics Market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Proteinuria Therapeutics Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline plc, Chinook Therapeutics Inc., Novartis International AG, AbbVie Inc., Calliditas Therapeutics AB, Travere Therapeutics Inc., Walden Biosciences, Ligand Pharmaceuticals Inc. and Retrophin, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Proteinuria Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Proteinuria Therapeutics Market
Market Segmentation
• By Drug Class
o Angiotensin-converting Enzyme (ACE) Inhibitors
o Angiotensin II Receptor Antagonists (ARBs)
o Diuretics
o Others
• By Route of Administration
o Oral
o Intravenous
• By Distribution Channels
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Regional Insights
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o GlaxoSmithKline plc
o Chinook Therapeutics Inc.
o Novartis International AG
o AbbVie Inc.
o Calliditas Therapeutics AB
o Travere Therapeutics Inc.
o Walden Biosciences
o Ligand Pharmaceuticals Inc.
o Retrophin, Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Preview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Class
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o Recent Product Launches
o Epidemiology
o Merger, Acquisition, and Collaboration
o Regulatory Scenario
o Key Developments
o PEST Analysis
o Partnership Scenario
o Brand and Pricing Analysis
o Distributors Landscape
o Porters Analysis
o Technological Advancements
o Key Developments
o Market Trend
o Future Prospective
o Top Market Players by Revenue
4. Global Proteinuria Therapeutics Market By Drug Class, 2026–2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022–2033
Segment Trends
o Angiotensin-converting Enzyme (ACE) Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
o Angiotensin II Receptor Antagonists (ARBs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
o Diuretics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
5. Global Proteinuria Therapeutics Market By Route of Administration, 2026-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022–2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
o Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
6. Global Proteinuria Therapeutics Market By Distribution Channel, 2026-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022–2033
Segment Trends
o Hospitals Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
7. Global Proteinuria Therapeutics Market By Region, 2026-2033, (USD Bn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, en2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, en2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, en2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Benelux
o Denmark
o Norway
o Sweden
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, en2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
o China
o Taiwan
o India
o Japan
o Indonesia
o Malaysia
o Philippines
o Singapore
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East & Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, en2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
o Bahrain
o Kuwait
o Oman
o Qatar
o Saudi Arabia
o UAE
o Israel
o South Africa
o North Africa
o Central Africa
o Rest of the Middle East
8. Competitive Landscape
o GlaxoSmithKline plc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
o Chinook Therapeutics Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
o Novartis International AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
o AbbVie Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
o Calliditas Therapeutics AB
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
o Travere Therapeutics Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
o Walden Biosciences
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
o Ligand Pharmaceuticals Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
o Retrophin, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
9. Section
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們